Akebia Therapeutics (AKBA) Current Assets (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Current Assets of $243.5 million for Q1 2026, up 19.48% year-over-year from $203.8 million in Q1 2025, and down 3.75% quarter-over-quarter from $253.0 million in Q4 2025.
Akebia Therapeutics (AKBA) Current Assets (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Current Assets for 14 consecutive years, with $243.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 19.48% year-over-year to $243.5 million; the TTM figure through Mar 2026 stood at $243.5 million (up 19.48% YoY), while the FY2025 annual figure was $253.0 million, up 122.22% from the prior year.
- Current Assets declined to $243.5 million in Q1 2026 per AKBA's latest filing, from $253.0 million in the prior quarter.
- Across five years, Current Assets topped out at $308.2 million in Q2 2022 and bottomed at $100.1 million in Q3 2024.
- Historically, Current Assets has averaged $184.7 million across 5 years, with a median of $185.2 million in 2022.
- Annual changes were most pronounced in 2023 — Current Assets sank 61.57% — and 2025, when it soared 158.03%.
- Akebia Therapeutics' Current Assets stood at $185.2 million in 2022, then sank by 36.2% to $118.1 million in 2023, then dropped by 3.65% to $113.8 million in 2024, then jumped by 122.22% to $253.0 million in 2025, then fell by 3.75% to $243.5 million in 2026.
- Business Quant data shows AKBA's Current Assets at $243.5 million in Q1 2026, $253.0 million in Q4 2025, and $258.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 5.76 Bn |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 13.76 Bn |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 6.36 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 19.76 Bn |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 3.48 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 10.06 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 1.64 Bn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 3.80 Bn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | 3.22 Bn |
| 10 | Akebia Therapeutics | 245.42 Mn | 89.87 Mn | 38.70 Mn | 229.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 229.55 Mn |
| Mar 31, 2026 | 243.48 Mn |
| Dec 31, 2025 | 252.96 Mn |
| Sep 30, 2025 | 258.34 Mn |
| Jun 30, 2025 | 234.66 Mn |
| Mar 31, 2025 | 203.78 Mn |
| Dec 31, 2024 | 113.83 Mn |
| Sep 30, 2024 | 100.12 Mn |
| Jun 30, 2024 | 112.10 Mn |
| Mar 31, 2024 | 112.94 Mn |
| Dec 31, 2023 | 118.15 Mn |
| Sep 30, 2023 | 109.60 Mn |
| Jun 30, 2023 | 118.45 Mn |
| Mar 31, 2023 | 120.80 Mn |
| Dec 31, 2022 | 185.18 Mn |
| Sep 30, 2022 | 242.21 Mn |
| Jun 30, 2022 | 308.25 Mn |
| Mar 31, 2022 | 305.14 Mn |
| Dec 31, 2021 | 271.15 Mn |
| Sep 30, 2021 | 330.08 Mn |